Scopus Biopharma Debt
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Scopus Biopharma holds a debt-to-equity ratio of 0.613. . Scopus Biopharma's financial risk is the risk to Scopus Biopharma stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Scopus Biopharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Scopus Biopharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the OTC Stock is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Scopus OTC Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Scopus Biopharma's stakeholders.
For most companies, including Scopus Biopharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Scopus Biopharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Scopus Biopharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Scopus Biopharma's debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Scopus Biopharma is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Scopus Biopharma to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Scopus Biopharma is said to be less leveraged. If creditors hold a majority of Scopus Biopharma's assets, the OTC Stock is said to be highly leveraged.
Scopus |
Scopus Biopharma Debt to Cash Allocation
Many companies such as Scopus Biopharma, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Scopus Biopharma currently holds 2.54 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Scopus Biopharma has a current ratio of 0.3, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Scopus Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Scopus Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Scopus Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Scopus to invest in growth at high rates of return. When we think about Scopus Biopharma's use of debt, we should always consider it together with cash and equity.Scopus Biopharma Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Scopus Biopharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Scopus Biopharma, which in turn will lower the firm's financial flexibility.Scopus Biopharma Corporate Bonds Issued
Understaning Scopus Biopharma Use of Financial Leverage
Scopus Biopharma's financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Scopus Biopharma's current equity. If creditors own a majority of Scopus Biopharma's assets, the company is considered highly leveraged. Understanding the composition and structure of Scopus Biopharma's outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Scopus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. Please read more on our technical analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.